Co-pay assistance programs are one of the most controversial topics in the managed care and biopharmaceutical industry today, with battle lines having long been drawn at the nexus of pharmaceutical manufacturers and managed care organizations. However, recent research highlights opportunities for finally blurring these lines and forging new partnerships. Read more. (Source: zitter Health Insights, 8/1/13).
You are here: / Blurring the Battle Lines